| Indoleamine 2, 3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin SM Vareki, M Rytelewski, R Figueredo, D Chen, PJ Ferguson, M Vincent, ... Oncotarget 5 (9), 2778, 2014 | 51 | 2014 |
| IDO downregulation induces sensitivity to pemetrexed, gemcitabine, FK866, and methoxyamine in human cancer cells S Maleki Vareki, D Chen, C Di Cresce, PJ Ferguson, R Figueredo, ... PloS one 10 (11), e0143435, 2015 | 43 | 2015 |
| Merger of dynamic two-photon and phosphorescence lifetime microscopy reveals dependence of lymphocyte motility on oxygen in solid and hematological tumors M Rytelewski, K Haryutyunan, F Nwajei, M Shanmugasundaram, ... Journal for immunotherapy of cancer 7, 1-13, 2019 | 39 | 2019 |
| BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis M Rytelewski, JG Tong, A Buensuceso, HS Leong, SM Vareki, ... Molecular oncology 8 (8), 1429-1440, 2014 | 38 | 2014 |
| CD5 blockade enhances ex vivo CD8+ T cell activation and tumour cell cytotoxicity F Alotaibi, M Rytelewski, R Figueredo, R Zareardalan, M Zhang, ... European journal of immunology 50 (5), 695-704, 2020 | 24 | 2020 |
| Suppression of Immunodominant Antitumor and Antiviral CD8+ T Cell Responses by Indoleamine 2,3-Dioxygenase M Rytelewski, CE Meilleur, M Atef Yekta, PA Szabo, N Garg, TD Schell, ... PloS one 9 (2), e90439, 2014 | 17 | 2014 |
| Inhibition of BRCA2 and thymidylate synthase creates multidrug sensitive tumor cells via the induction of combined “complementary lethality” M Rytelewski, PJ Ferguson, SM Vareki, R Figueredo, M Vincent, ... Molecular Therapy-Nucleic Acids 2, 2013 | 17 | 2013 |
| Preventing and curing citrulline‐induced autoimmune arthritis in a humanized mouse model using a Th2‐polarizing iNKT cell agonist KM Walker, M Rytelewski, DM Mazzuca, SA Meilleur, LA Mannik, D Yue, ... Immunology and cell biology 90 (6), 630-639, 2012 | 17 | 2012 |
| Inhibition of oxidative phosphorylation reverses bone marrow hypoxia visualized in imageable syngeneic B-ALL mouse model M Rytelewski, K Harutyunyan, N Baran, S Mallampati, MA Zal, A Cavazos, ... Frontiers in Oncology 10, 991, 2020 | 15 | 2020 |
| Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer DJ Schofield, J Percival-Alwyn, M Rytelewski, J Hood, R Rothstein, ... MAbs 13 (1), 1857100, 2021 | 12 | 2021 |
| Reciprocal positive selection for weakness-preventing olaparib resistance by inhibiting BRCA2 M Rytelewski, SM Vareki, LS Mangala, L Romanow, D Jiang, S Pradeep, ... Oncotarget 7 (15), 20825, 2016 | 10 | 2016 |
| siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine C Di Cresce, R Figueredo, M Rytelewski, SM Vareki, C Way, PJ Ferguson, ... Oncotarget 6 (26), 22397, 2015 | 9 | 2015 |
| Differential Regulation of Simultaneous Antitumor and Alloreactive CD8+ T‐Cell Responses in the Same Host by Rapamycin SM Vareki, MJ Harding, J Waithman, D Zanker, AN Shivji, M Rytelewski, ... American Journal of Transplantation 12 (1), 233-239, 2012 | 8 | 2012 |
| Methods of treating cancer by inhibition of dna repair proteins M Vincent, PJ Ferguson, M Rytelewski WO Patent EP2683825 A1, WO2012122645A1, 2014 | 5 | 2014 |
| Antisense technology: from unique laboratory tool to novel anticancer treatments C Di Cresce, C Way, M Rytelewski, SM Vareki, S Nilam, MD Vincent, ... From Nucleic Acids Sequences to Molecular Medicine, 145-189, 2012 | 4 | 2012 |
| Evaluating the effectiveness of cancer drug sensitization in vitro and in vivo M Rytelewski, A Buensuceso, HS Leong, BJ Deroo, AF Chambers, ... JoVE (Journal of Visualized Experiments), e52388, 2015 | 3 | 2015 |
| Intravital Imaging of Bright Cyan-Fluorescent AML Model Reveals Impact of CXCR4 Inhibitor on AML and Immune Cell Dynamics T Zal, M Rytelewski, R Jacamo, MA Zal, M Shanmugasundaram, ... Blood 134, 2674, 2019 | 1 | 2019 |
| Interaction of Leukemia and Bone Marrow Microenvironment in Mouse ALL Model is Associated with Disorganized Vasculature and Progressive Hypoxia K Harutyunyan, M Konopleva, S Mallampati, M Rytelewski, T Zal, C Wood, ... Clinical Lymphoma, Myeloma and Leukemia 17, S259-S260, 2017 | 1 | 2017 |
| Sensitization of human tumor cells to chemotherapy drugs by antisense downregulation of RAD51: targeting DNA repair to induce synthetic lethality PJ Ferguson, M Rytelewski, MD Vincent, J Koropatnick Cancer Research 76 (14_Supplement), 3718-3718, 2016 | 1 | 2016 |
| Overcoming Innate and Acquired Therapy Resistance by Targeting DNA Repair in Human Cancer Cells M Rytelewski The University of Western Ontario (Canada), 2015 | 1 | 2015 |
Tomasz Zal, Ph.D.University of Texas, MD Anderson Cancer CenterVerified email at mdanderson.org
